FDA Extends Comment Period for Generic Safety Labeling Rule

Washington Drug Letter
The FDA has extended by 60 days the comment period for its proposed safety labeling rule for generic drugs. Stakeholders now have until March 13 to comment on the proposal, which would allow generic drugmakers to update labels in response to safety issues without agency approval.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00